Somatostatin Receptor 5 and Cannabinoid Receptor 1 Activation Inhibit Secretion of Glucose-dependent Insulinotropic Polypeptide from Intestinal K Cells in Rodents

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2012 Aug 9

PMID 22872212

Citations 35

Authors

C E Moss

W J Marsh

H E Parker

E Ogunnowo-Bada

C H Riches

A M Habib

M L Evans

F M Gribble

F Reimann

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: Glucose-dependent insulinotropic polypeptide (GIP) is an enteroendocrine hormone that promotes storage of glucose and fat. Its secretion from intestinal K cells is triggered by nutrient ingestion and is modulated by intracellular cAMP. In view of the proadipogenic actions of GIP, this study aimed to identify pathways in K cells that lower cAMP levels and GIP secretion.

Methods: Murine K cells purified by flow cytometry were analysed for expression of G(αi)-coupled receptors by transcriptomic microarrays. Somatostatin and cannabinoid receptor expression was confirmed by quantitative RT-PCR. Hormone secretion in vitro was measured in GLUTag and primary murine intestinal cultures. cAMP was monitored in GLUTag cells using the genetically encoded sensor Epac2-camps. In vivo tolerance tests were performed in cannulated rats.

Results: Purified murine K cells expressed high mRNA levels for somatostatin receptors (Sstrs) Sstr2, Sstr3 and Sstr5, and cannabinoid receptor type 1 (Cnr1, CB1). Somatostatin inhibited GIP and glucagon-like peptide-1 (GLP-1) secretion from primary small intestinal cultures, in part through SSTR5, and reduced cAMP generation in GLUTag cells. Although the CB1 agonist methanandamide (mAEA) inhibited GIP secretion, no significant effect was observed on GLP-1 secretion from primary cultures. In cannulated rats, treatment with mAEA prior to an oral glucose tolerance test suppressed plasma GIP but not GLP-1 levels, whereas the CB1 antagonist AM251 elevated basal GIP concentrations.

Conclusions/interpretation: GIP release is inhibited by somatostatin and CB1 agonists. The differential effects of CB1 ligands on GIP and GLP-1 release may provide a new tool to dissociate secretion of these incretin hormones and lower GIP but not GLP-1 levels in vivo.

Citing Articles

Differential Impact of Medical Therapies for Acromegaly on Glucose Metabolism.

Gatto F, Arecco A, Amaru J, Arvigo M, Campana C, Milioto A Int J Mol Sci. 2025; 26(2).

PMID: 39859181 PMC: 11764544. DOI: 10.3390/ijms26020465.

G Protein-Coupled Receptor 17 Inhibits Glucagon-like Peptide-1 Secretion via a Gi/o-Dependent Mechanism in Enteroendocrine Cells.

Conley J, Jochim A, Evans-Molina C, Watts V, Ren H Biomolecules. 2025; 15(1).

PMID: 39858405 PMC: 11762167. DOI: 10.3390/biom15010009.

Single-cell transcriptomics of human organoid-derived enteroendocrine cell populations from the small intestine.

Smith C, Lu V, Bany Bakar R, Miedzybrodzka E, Davison A, Goldspink D J Physiol. 2024; .

PMID: 39639676 PMC: 7617304. DOI: 10.1113/JP287463.

G protein-coupled receptor 17 inhibits glucagon-like peptide-1 secretion via a Gi/o-dependent mechanism in enteroendocrine cells.

Conley J, Jochim A, Evans-Molina C, Watts V, Ren H bioRxiv. 2024; .

PMID: 39605686 PMC: 11601441. DOI: 10.1101/2024.11.13.623413.

Molecular mechanisms underlying glucose-dependent insulinotropic polypeptide secretion in human duodenal organoids.

Guccio N, Alcaino C, Miedzybrodzka E, Santos-Hernandez M, Smith C, Davison A Diabetologia. 2024; 68(1):217-230.

PMID: 39441374 PMC: 11663192. DOI: 10.1007/s00125-024-06293-3.

References

Osundiji M, Zhou L, Shaw J, Moore S, Yueh C, Sherwin R . Brain glucosamine boosts protective glucoprivic feeding. Endocrinology. 2010; 151(4):1499-508. PMC: 2850228. DOI: 10.1210/en.2009-0989. View

Gomez R, Navarro M, Ferrer B, Trigo J, Bilbao A, Del Arco I . A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci. 2002; 22(21):9612-7. PMC: 6758016. View

Pang Z, Wu N, Zhao W, Chain D, Schaffer E, Zhang X . The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice. Obesity (Silver Spring). 2011; 19(10):1923-34. DOI: 10.1038/oby.2011.250. View

Nikolaev V, Bunemann M, Hein L, Hannawacker A, Lohse M . Novel single chain cAMP sensors for receptor-induced signal propagation. J Biol Chem. 2004; 279(36):37215-8. DOI: 10.1074/jbc.C400302200. View

Reimann F, Habib A, Tolhurst G, Parker H, Rogers G, Gribble F . Glucose sensing in L cells: a primary cell study. Cell Metab. 2008; 8(6):532-9. PMC: 2697331. DOI: 10.1016/j.cmet.2008.11.002. View

Quarta C, Mazza R, Obici S, Pasquali R, Pagotto U . Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol Med. 2011; 17(9):518-26. DOI: 10.1016/j.molmed.2011.05.002. View

Baggio L, Drucker D . Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132(6):2131-57. DOI: 10.1053/j.gastro.2007.03.054. View

Kieffer T, Buchan A, Barker H, Brown J, PEDERSON R . Release of gastric inhibitory polypeptide from cultured canine endocrine cells. Am J Physiol. 1994; 267(4 Pt 1):E489-96. DOI: 10.1152/ajpendo.1994.267.4.E489. View

Habib A, Richards P, Cairns L, Rogers G, Bannon C, Parker H . Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology. 2012; 153(7):3054-65. PMC: 3440453. DOI: 10.1210/en.2011-2170. View

10.

Jarbe T, Liu Q, Makriyannis A . Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats. Psychopharmacology (Berl). 2005; 184(1):36-45. DOI: 10.1007/s00213-005-0225-y. View

11.

Gorboulev V, Schurmann A, Vallon V, Kipp H, Jaschke A, Klessen D . Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes. 2011; 61(1):187-96. PMC: 3237647. DOI: 10.2337/db11-1029. View

12.

Kieffer T . GIP or not GIP? That is the question. Trends Pharmacol Sci. 2003; 24(3):110-2. DOI: 10.1016/S0165-6147(03)00031-2. View

13.

Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y . Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A. 1999; 96(26):14843-7. PMC: 24735. DOI: 10.1073/pnas.96.26.14843. View

14.

Hansen K, Rosenkilde M, Knop F, Wellner N, Diep T, Rehfeld J . 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. J Clin Endocrinol Metab. 2011; 96(9):E1409-17. DOI: 10.1210/jc.2011-0647. View

15.

Petersen G, Sorensen C, Schmid P, Artmann A, Tang-Christensen M, Hansen S . Intestinal levels of anandamide and oleoylethanolamide in food-deprived rats are regulated through their precursors. Biochim Biophys Acta. 2006; 1761(2):143-50. DOI: 10.1016/j.bbalip.2005.12.011. View

16.

Izzo A, Sharkey K . Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010; 126(1):21-38. DOI: 10.1016/j.pharmthera.2009.12.005. View

17.

Althage M, Ford E, Wang S, Tso P, Polonsky K, Wice B . Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J Biol Chem. 2008; 283(26):18365-76. PMC: 2440595. DOI: 10.1074/jbc.M710466200. View

18.

Yip R, Boylan M, Kieffer T, Wolfe M . Functional GIP receptors are present on adipocytes. Endocrinology. 1998; 139(9):4004-7. DOI: 10.1210/endo.139.9.6288. View

19.

Butler H, Korbonits M . Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists. Eur J Endocrinol. 2009; 161(5):655-62. PMC: 2761811. DOI: 10.1530/EJE-09-0511. View

20.

Mortensen K, Christensen L, Holst J, Orskov C . GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept. 2003; 114(2-3):189-96. DOI: 10.1016/s0167-0115(03)00125-3. View